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INTRODUCTION
Histiocytic sarcoma (HS), a rare hematopoietic neoplasm
with aggressive characteristics and poor outcomes, can pre-
sent as localized disease confined to the skin, lymph nodes,
and intestinal tract, or as disseminated disease (1, 2). These
histiocytic and dendritic cell neoplasms arise from antigen-
processing phagocytes and antigen-presenting dendritic cells,
cells derived from hematopoietic or mesenchymal stem cells
(1). HS has often been mistaken for some types of lymphomas,
due to their overlapping features and inadequate phenotyp-
ic evaluation, particularly immunohistochemical and cyto-
genetic data (2, 3). Current HS diagnosis is based on histo-
logical and immunohistochemical evidence of histiocytic dif-
ferentiation and the exclusion of epithelial, melanocytic, and
lymphoid phenotypes (4). Using both immunohistochem-
istry and cytogenetics, it is now generally accepted that most
neoplasms diagnosed as HS were actually B- or T-cell, non-
Hodgkin lymphomas (1, 4).
HS is a malignancy characterized by the proliferation of
histiocytes with positive expression of the macrophage asso-
ciated antigen CD68; negative expression of the T-cell asso-
ciated and Langerhans cell antigen CD1a, S-100 protein, and
the dendritic cell-associated antigens CD21 and CD35; and
also the absence of Birbeck granules, junctions, desmosomes
and cytoplasmic projections on electron microscopy (1-6).
Although several cases of HS have been described (4-12), pri-
mary bone marrow (BM) involvement is rare. We describe
here a patient with HS showing primary BM involvement. 
CASE REPORT
A 63-yr-old male complaining of weight loss (10 kg in 6
months), fever of unknown origin and general weakness was
referred to our hospital for evaluation. Previous medical his-
tory, family history and physical examination showed nothing
remarkable. At presentation, white blood cell (WBC) count
was 13.2×103/mL, hemoglobin was 9.4 g/dL and platelet
count was 466×103/mL. Prothrombin time and activated par-
tial thromboplastin time were near normal range. His serum
protein concentration was 7.5 mg/dL, albumin was 1.4 mg/
dL, aspartate aminotransferase was 53 IU/L, alanine amino-
transferase was 53 IU/L, alkaline phosphatase was 496 IU/L,
g-GT was 66 IU/L, total bilirubin was 0.7 mg/dL, lactate
dehydrogenase was 231 IU/L and C-reactive protein was 26.42
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A Case of Histiocytic Sarcoma Presenting with Primary Bone Marrow
Involvement
Histiocytic sarcoma (HS) is a very rare neoplasm that often shows an aggressive
clinical course and systemic symptoms, such as fever, weight loss, adenopathy,
hepatosplenomegaly and pancytopenia. It may present as localized or disseminat-
ed disease. We describe here a 63-yr-old male who manifested systemic symp-
toms, including fever, weight loss and generalized weakness. Abdominal and chest
computed tomography failed to show specific findings, but there was suspicion of
multiple bony changes at the lumbar spine. Fusion whole body positron emission
tomography, bone scan and lumbar spine magnetic resonance imaging showed
multiple bone lesions, suggesting a malignancy involving the bone marrow (BM).
Several BM and bone biopsies were inconclusive for diagnosis. Necropsy showed
replacement of the BM by a diffuse proliferation of neoplastic cells with markedly
increased cellularity (95%). The neoplastic cells were positive for lysozyme and
CD68, but negative for T- and B-cell lineage markers, and megakaryocytic, epithe-
lial, muscular and melanocytic markers. Morphologic findings also distinguished it
from other dendritic cell neoplasms. 
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sium was 4.4 mM/L, chloride was 93 mM/L and total CO2
was 29.0 mM/L. His ferritin concentration was 2,339.3 ng/
mL and fibrinogen concentration was 552 mg/dL. Review of
abdominal and chest computed tomography (CT) performed
at the referring hospital showed nothing unusual, except for
a few 1-cm-sized small lymph nodes and mild hepatosple-
nomegaly. Head and neck CT revealed slight enlargement
of a neck lymph node, which may have been benign or metas-
tatic, but two target biopsies and an excisional biopsy of the
lesion provided no diagnostic information. Abdominal and
pelvic CT performed at our hospital showed the same results
as the CT scans performed at the referring hospital, except for
suspicion of bony changes at the lumbar and sacral bones. 
Although fusion whole body positron emission tomogra-
phy (PET) showed lesions indicative of multiple bone metas-
tases (Fig. 1A), a bone scan showed little osteoblastic reaction
(Fig. 1B). Because there was no evidence of malignancy on
chest, abdominal and pelvic CT and prostate ultrasonogra-
phy, we performed lumbar spine magnetic resonance imag-
ing (MRI) (Fig. 2). The MRI findings suggested that the PET
lesions were reactive changes of the BM caused by malignant
cell infiltration, such as leukemia, lymphoma or multiple
myeloma (MM) rather than multiple bone metastases. 
A BM biopsy showed an increase in plasma cells (15%),
eosinophils and histiocytes, but no malignant cells. Due to
suspected MM, we tested the monoclonality of the plasma-
cytosis and fluorescence in situ hybridization myeloma panel.
Although b2-microglobulin was 3.6 mcg/mL, there was no
evidence of monoclonality in plasmacytosis, IGH/FGFR3
rearrangement, or RB1 or TP53 deletion. The serum concen-
tration of kappa free light chain (FLC) was 81.10 mg/L, the
serum concentration of lambda FLC was 139.00 mg/L and
the kappa/lambda FLC ratio was 0.58. Serum protein elec-
trophoresis and immunoelectrophoresis showed increases in
a-1, 2 and g-globulin fractions, findings consistent with a
chronic inflammatory response. CT guided bone biopsies of
the lumbar spine and another BM biopsy showed no evidence
of malignant cells. The patient chose supportive care, but was
readmitted one month later for aggravation of his general con-
dition. Abdominal and pelvic CT showed no changes except
for apparent bony changes. The patient still wanted support-
ive care and died soon afterward. 
At necropsy, we performed another BM biopsy and a liver
biopsy. The liver biopsy showed no evidence of malignancy,
except for severe cholestasis with non-specific hepatitis. The
BM biopsy, however, revealed a diffuse non-cohesive prolifer-
ation of pleomorphic neoplastic cells with large round to oval
nuclei, vesicular chromatin and abundant foamy eosinophilic
cytoplasm (Fig. 3). Immunohistochemistry showed positive
expression of CD68 (macrophage/histiocytic marker), S100
protein, CD31, CD99 and Vimentin. Neoplastic cells were
weakly positive for CD21 (mature B-cell and follicular den-
dritic cell marker), CD4 (T-cell marker) and lysozyme and
negative for CD3 (T-cell marker), CD20/CD79a (B-cell mark-
ers), CD56 (NK cell marker), cytokeratin, smooth muscle
actin (SMA, a myeloid cell marker), SMMHC and HMB45.
Staining showed Masson-Trichrome positive fine collagen
fibers and PAS positivity on megakaryocytes. Together, these
morphologic and immunohistochemical features are consis-
tent with the BM involvement of HS.
DISCUSSION
HS is a rare and aggressive malignant disorder commonly
presenting at extranodal sites and showing a poor response to
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Fig. 1. Scanning findings for bones. (A) Disseminated hyperme-
tabolic lesion (maxSUV=9.0, L2 body) at the whole spine by PET.
A hypermetabolic lesion suggesting a primary malignant lesion
was not detected in the lung, intraabdominal and pelvic organs.
(B) No increased bone uptake of hypermetabolic lesions on bone
scan, with little osteoblastic effect.
A B
Fig. 2. Diffuse and heterogeneous T1 and T2 showing low SI
changes in the lower thoracic and lumbar spine with subtle en-
hancement.therapy, with most patients dying from the disease (1). Some
patients show systemic presentation, with features of malig-
nant histiocytosis. HS may also be associated with other hema-
tological disorders, such as acute leukemia, lymphoma and
myelodysplasia (1, 7). Genetic or epigenetic inactivation of
PTEN, p16INK4A, and p14ARF has been observed in HS,
indicating that these proteins are involved in the development
of HS and providing insights into the pathogenesis of these
tumors (13).
Differential diagnosis of HS includes Langerhans cell sar-
coma (LCS), diffuse large B-cell lymphoma, peripheral T-cell
lymphoma, anaplastic large cell lymphoma (ALCL), metastat-
ic carcinoma, and melanoma. The diagnosis of HS is based
on histological and immunohistochemical evidence of histi-
ocytic differentiation and exclusion of other malignancies with
epithelial, melanocytic and lymphoid phenotypes (4). Malig-
nant HS cells strongly express the hemoglobin scavenger mark-
er CD163, which is regarded as a specific marker for HS (4).
Tumor cells in our patient showed expression of histiocyt-
ic markers (CD68) and lysozyme with weak expression of
CD21. The cells, however, did not express B-cell, T-cell, and
myeloid markers, including CD3, CD20, CD56, and CD79a,
or SMA and SMMHC. The expression of histiocytic markers
was unusual for ALCL, and no rearrangement of the T-cell
receptor g-chain gene was identified. Although these cells
showed expression of S100 protein, the latter may have been
derived from activated normal macrophages (1, 9). Metastat-
ic carcinoma and melanoma were ruled out by the absence
of expression of cytokeratins and HMB45 (9).
Morphologically, tumor cells in LCS have nuclei that are
grooved, indented, folded, or lobulated, with fine chromatin
and a thin nuclear membrane, features that are absent in HS
(2, 9). The tumor cells in our patient had abundant clear cyto-
plasm, without spindle or fusiform cells, showing a whorled,
fascicular or storiform pattern. These morphologic differences
could distinguish the disease in our patient from LCS, and
from follicular and interdigitating dendritic cell tumors (1). 
HS shows a very aggressive clinical course in most patients.
In one study, 6 of 11 patients died of disease within 0.5 to
36 months (10). In a study of 18 patients who underwent
chemotherapy, 3 achieved complete remission, 6 had no res-
ponse, and 7 died of disease (1). In another study of four adult
patients with widespread disease, all failed chemotherapy and
died from disease within 0.5 to 14 months after diagnosis
(14). In other studies, 6 of 8 adult patients died of disease 5
to 48 months after diagnosis despite aggressive chemother-
apy (15). The patient described here died of disease 2 months
after his first visit to our hospital.
Due to the rarity of this malignancy, chemotherapy regi-
mens have not been standardized, with most studies being
retrospective reviews (8). Nonetheless, chemotherapy used
to treat large cell lymphomas is a reasonable approach for
patients with HS (12), although thalidomide may also ben-
efit these patients (3, 11).
In summary, HS is a rare neoplasm difficult to pathologi-
cally diagnose. Immunohistochemical features suggesting
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Fig. 3. Histopathological findings of bone marrow biopsy. (A) Non-cohesive proliferation of large pleomorphic neoplastic cells with large
round-to-oval nuclei with vesicular chromatin and abundant foamy cytoplasm (H&E stain, ×400). Immunostaining with antibodies to (B)
CD99, (C) CD68, (D) CD56, (E) HMB45 (each, ×100) and (F) S100 (×200).
B C A
E F DHS include the strong expression of histiocytic markers such
as CD68, lysozyme and CD163. Proper recognition of HS
is important, because the clinical presentation and morpho-
logic appearance of this neoplasm may lead to a misdiagno-
sis as other hematologic malignancies. 
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